Should I buy or sell Singular Genomics Systems stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares. View OMIC analyst ratings or view top-rated stocks .

What is Singular Genomics Systems' stock price target for 2024?

1 analysts have issued 1 year price objectives for Singular Genomics Systems' stock. Their OMIC share price targets range from $1.00 to $1.00. On average, they predict the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 139.8% from the stock's current price. View analysts price targets for OMIC or view top-rated stocks among Wall Street analysts .

How have OMIC shares performed in 2023?

Singular Genomics Systems' stock was trading at $2.01 at the beginning of the year. Since then, OMIC shares have decreased by 79.3% and is now trading at $0.4170. View the best growth stocks for 2023 here .

Are investors shorting Singular Genomics Systems?

Singular Genomics Systems saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,540,000 shares, an increase of 40.0% from the October 31st total of 1,100,000 shares. Based on an average daily trading volume, of 600,400 shares, the short-interest ratio is currently 2.6 days. Approximately 3.7% of the company's stock are sold short. View Singular Genomics Systems' Short Interest .

When is Singular Genomics Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024. View our OMIC earnings forecast .

How were Singular Genomics Systems' earnings last quarter?

Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its earnings results on Tuesday, November, 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. Singular Genomics Systems had a negative net margin of 3,571.18% and a negative trailing twelve-month return on equity of 40.38%.

When did Singular Genomics Systems IPO?

(OMIC) raised $178 million in an IPO on Thursday, May 27th 2021. The company issued 8,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank acted as the underwriters for the IPO.

Who are Singular Genomics Systems' major shareholders?

Singular Genomics Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.82%), UBS Group AG (3.02%), QVIDTVM Management LLC (1.63%), Acuitas Investments LLC (0.71%), Platinum Investment Management Ltd. (0.58%) and Jacobs Levy Equity Management Inc. (0.49%). Insiders that own company stock include Andrew Spaventa, Eli N Glezer, James E Flynn, Kim P Kamdar, Michael J Pellini and Sheryl L Conley. View institutional ownership trends .

How do I buy shares of Singular Genomics Systems?

Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Singular Genomics Systems Stock Price, News & Analysis (NASDAQ:OMIC)

$0.42

+0.03 (+7.75%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.39
▼
$0.42
50-Day Range: $0.33
▼
$0.58
52-Week Range: $0.31
▼
$3.00

Volume: 173,016 shs
Average Volume: 1.50 million shs
Market Capitalization: $30.60 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.00

Singular Genomics Systems MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 139.8% Upside
$1.00 Price Target
Short Interest: Healthy
3.68% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$103,822 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.46) to ($1.55) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

327th out of 951 stocks

Analytical Instruments Industry

13th out of 29 stocks

3.0

Analyst's Opinion

Consensus Rating
Singular Genomics Systems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.00, Singular Genomics Systems has a forecasted upside of 139.8% from its current price of $0.42.
Amount of Analyst Coverage
Singular Genomics Systems has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.68% of the float of Singular Genomics Systems has been sold short.
Short Interest Ratio / Days to Cover
Singular Genomics Systems has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Singular Genomics Systems has recently increased by 40.00%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Singular Genomics Systems does not currently pay a dividend.
Dividend Growth
Singular Genomics Systems does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OMIC.

3.0

News and Social Media Coverage

News Sentiment
Singular Genomics Systems has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Singular Genomics Systems this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for OMIC on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Singular Genomics Systems to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Singular Genomics Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $103,822.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
21.90% of the stock of Singular Genomics Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
55.75% of the stock of Singular Genomics Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Singular Genomics Systems are expected to decrease in the coming year, from ($1.46) to ($1.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Singular Genomics Systems is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Singular Genomics Systems is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Singular Genomics Systems has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Singular Genomics Systems Stock (NASDAQ:OMIC)

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

OMIC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OMIC Stock News Headlines

November 21, 2023 | finance.yahoo.com

Singular Genomics Systems Founder Acquires 4.6% More Stock

November 16, 2023 | markets.businessinsider.com

Hold Rating on Singular Genomics Systems (OMIC) Amid Q3 Underperformance and Strategy Shift

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 16, 2023 | finanznachrichten.de

Singular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results

November 14, 2023 | benzinga.com

Recap: Singular Genomics Sys Q3 Earnings

November 14, 2023 | seekingalpha.com

OMIC Singular Genomics Systems, Inc.

November 4, 2023 | morningstar.com

Singular Genomics Systems Inc OMIC

October 24, 2023 | finance.yahoo.com

Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023

December 2, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

September 28, 2023 | finance.yahoo.com

Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now

September 8, 2023 | finance.yahoo.com

Singular Genomics to Present at the Gilmartin Group Emerging Growth Company Showcase

August 11, 2023 | finanznachrichten.de

Singular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and Second Quarter 2023 Financial Results

August 10, 2023 | msn.com

Goldman Sachs Maintains Singular Genomics Systems (OMIC) Neutral Recommendation

August 9, 2023 | msn.com

Singular Genomics Systems GAAP EPS of -$0.35, revenue of $0.5M

August 8, 2023 | finance.yahoo.com

Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

July 27, 2023 | finance.yahoo.com

Singular Genomics to Report Second Quarter 2023 Financial Results on August 9, 2023

June 1, 2023 | finance.yahoo.com

Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference

May 11, 2023 | msn.com

Singular Genomics Systems GAAP EPS of $0.33 beats by $0.69, revenue of $0.86M misses by $0.38M

May 10, 2023 | finanznachrichten.de

Singular Genomics Systems, Inc.: Singular Genomics Reports Recent Highlights and First Quarter 2023 Financial Results

May 10, 2023 | finance.yahoo.com

Q1 2023 Singular Genomics Systems Inc Earnings Call

May 10, 2023 | msn.com

Singular Genomics Sys's Earnings Outlook

May 9, 2023 | msn.com

Recap: Singular Genomics Sys Q1 Earnings

May 7, 2023 | benzinga.com

Singular Genomics Sys Stock (NASDAQ:OMIC), Guidance and Forecast

May 6, 2023 | benzinga.com

Singular Genomics Sys Stock (NASDAQ:OMIC), Dividends

May 4, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and InMode (INMD)

March 6, 2023 | finance.yahoo.com

Singular Genomics Systems, Inc. (NASDAQ:OMIC) Q4 2022 Earnings Call Transcript

March 3, 2023 | finance.yahoo.com

Q4 2022 Singular Genomics Systems Inc Earnings Call

See More Headlines

Receive OMIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Singular Genomics Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/07/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OMIC
CUSIP: N/A
CIK: 1850906
Web: singulargenomics.com
Phone: 858-333-7830
Fax: N/A
Employees: 269
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.00
High Stock Price Target: $1.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +139.8%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-90,880,000.00
Net Margins: -3,571.18%
Pretax Margin: -3,571.18%
Return on Equity: -40.38%
Return on Assets: -30.84%

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 13.64
Quick Ratio: 12.77

Sales & Book Value

Annual Sales: $760,000.00
Price / Sales: 40.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.71 per share
Price / Book: 0.15

Miscellaneous

Outstanding Shares: 73,390,000
Free Float: 57,314,000
Market Cap: $30.60 million
Optionable: Not Optionable
Beta: 1.19

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Andrew Spaventa (Age 38)
Founder, CEO, President & Chairperson of the Board
Comp: $685.93k
Dr. David L. Barker Ph.D. (Age 81)
Founder, Member of Scientific Advisory Board & Independent Director
Comp: $63.75k
Dr. Eli N. Glezer Ph.D. (Age 54)
Founder, Chief Scientific Officer & Chair of Scientific Advisory Board
Comp: $496.5k
Mr. Dalen Meeter (Age 45)
Chief Financial Officer
Comp: $434.39k
Jyotsna Ghai
Chief Operating Officer
Mr. Jorge Velarde Jr. (Age 56)
MBA, Senior Vice President of Corporate Development & Strategy
Mr. Jeff Bullard
Head of Sales
Mr. Vincent Brancaccio (Age 40)
Head of Human Resources
Mr. Samuel Ropp Ph.D. (Age 49)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OMIC Stock Analysis - Frequently Asked Questions

Should I buy or sell Singular Genomics Systems stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Singular Genomics Systems in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" OMIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMIC, but not buy additional shares or sell existing shares.
View OMIC analyst ratings or view top-rated stocks.
What is Singular Genomics Systems' stock price target for 2024?: 1 analysts have issued 1 year price objectives for Singular Genomics Systems' stock. Their OMIC share price targets range from $1.00 to $1.00. On average, they predict the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 139.8% from the stock's current price.
View analysts price targets for OMIC or view top-rated stocks among Wall Street analysts.
How have OMIC shares performed in 2023?: Singular Genomics Systems' stock was trading at $2.01 at the beginning of the year. Since then, OMIC shares have decreased by 79.3% and is now trading at $0.4170.
View the best growth stocks for 2023 here.
Are investors shorting Singular Genomics Systems?: Singular Genomics Systems saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 1,540,000 shares, an increase of 40.0% from the October 31st total of 1,100,000 shares. Based on an average daily trading volume, of 600,400 shares, the short-interest ratio is currently 2.6 days. Approximately 3.7% of the company's stock are sold short.
View Singular Genomics Systems' Short Interest.
When is Singular Genomics Systems' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our OMIC earnings forecast.

How were Singular Genomics Systems' earnings last quarter?: Singular Genomics Systems, Inc. (NASDAQ:OMIC) announced its earnings results on Tuesday, November, 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. Singular Genomics Systems had a negative net margin of 3,571.18% and a negative trailing twelve-month return on equity of 40.38%.
When did Singular Genomics Systems IPO?: (OMIC) raised $178 million in an IPO on Thursday, May 27th 2021. The company issued 8,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Goldman Sachs, BofA Securities, Cowen and UBS Investment Bank acted as the underwriters for the IPO.
Who are Singular Genomics Systems' major shareholders?: Singular Genomics Systems' stock is owned by many different retail and institutional investors. Top institutional shareholders include Deerfield Management Company L.P. Series C (6.82%), UBS Group AG (3.02%), QVIDTVM Management LLC (1.63%), Acuitas Investments LLC (0.71%), Platinum Investment Management Ltd. (0.58%) and Jacobs Levy Equity Management Inc. (0.49%). Insiders that own company stock include Andrew Spaventa, Eli N Glezer, James E Flynn, Kim P Kamdar, Michael J Pellini and Sheryl L Conley.
View institutional ownership trends.
How do I buy shares of Singular Genomics Systems?: Shares of OMIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OMIC) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial